ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients

Li, Kang; Liu, Jun; Wu, Lin; Xiao, Yajie; Li, Jia; Du, Haijian; Zhao, Zhikun; Sun, Chao; Zhao, Yongtian; Yang, Jie; Wu, Dongfang; Zhao, Zhuxiang*; Chen, Bolin*1
Cancer Cell International2022-3-27DOI: 10.1186/s12935-022-02488-z
7被引7阅读
引用收藏
分享

摘要

Background Although PD-L1 expression is a crucial predictive biomarker for immunotherapy, it can be influenced by many factors. Methods A total of 248 Chinese patients with lung adenocarcinoma was retrospectively identified. Data for clinical features, gene alternations, signaling pathways and immune signatures was analyzed among negative expression group (TPS < 1%, n = 124), intermediate expression group (1% <= TPS < 50%, n = 93), and high expression group (TPS >= 50%, n = 38). Clinical outcomes among different expression groups were also evaluated from public database. Results Firstly, high tumor mutation burden was significantly associated with high PD-L1 expression in these Chinese patients with lung adenocarcinoma. In addition, gene alternations including TP53, PRKDC, KMT2D, TET1 and SETD2 apparently occurred in high PD-L1 expression group. Moreover, pathway analysis showed that mutations involving in DDR pathway, TP53 pathway, cell-cycle pathway and NOTCH pathway were obviously varied among three PD-L1 expression groups. Besides, most of patients in high PD-L1 expression group from TCGA database were determined as high-grade immune subtypes (C2-C4), showing significant higher proportions of IFN-gamma, CD8+ T-cells, NK cells, NK CD56 dim cells, Th1 cells, Th2 cells (P < 0.0001). Moreover, SETD2 mutation slightly correlated with overall survival from MSKCC cohort (HR 1.92 [95%CI 0.90-4.10], P = 0.085), and the percentage of IFN-gamma was significantly higher in SETD2 mutant group than in wild-type group (P < 0.01). Conclusions This study illustrated in-depth genomic correlates of PD-L1 expression in Chinese lung adenocarcinoma patients and relevant immune signatures from public database, which might interpret more potential molecular mechanisms for immunotherapy in NSCLC.

学科与关键词

关键词
PD-L1 expressionLung adenocarcinomaGenomic profileImmune signatureImmunotherapy
相关
加载中…
  • Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
    Li, Yue; Li, Chong; Jiang, Ya; Han, Xue; Liu, Sisi; Xu, Xiuxiu; Tang, Wanxiangfu; Ou, Qiuxiang; Bao, Hua; Wu, Xue; Shao, Yang; Xing, Minyan; Zhang, Yixiang*; Wang, Yuezhen*Journal of Oncology, 2022, 2022: 1763778.被引 1
  • In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.
    Kang, Li; Liu, Jun; Li, Jia; Wu, Lin; Xiao, Yajie; Du, Haijian; Zhao, Zhikun; Li, Xiaoting; Wu, Dongfang; Zhao, Zhuxiang; Chen, BolinVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
  • Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations
    Li, Kai; Cao, Li; Li, Cheukfai; Wu, Jundong; Chen, Bo; Zhang, Guochun; Li, Xueri; Wen, Lingzhu; Jia, Minghan; Wei, Guangnan; Lin, Jiali; Li, Yingzi; Zhang, Yuchen; Mok, Hsiaopei; Ren, Chongyang; Wang, Yulei; Qi, Xiaofang; Guo, Lijie; Che, Yue; Liao, Ning*Cancer Medicine, 2023, 12(5): 5195-5208.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Cell International
发表日期
2022-03-27
卷期
第 22 卷, 第 1 期
页码
138
DOI
10.1186/s12935-022-02488-z
语言
ENGLISH
期刊等级
3区
成果收录
SCIE

作者

  • L

    Li, Kang (第一作者)

    2 · hunan canc hosp

  • L

    Liu, Jun

    1

查看全部 13 位作者收起作者
  • W

    Wu, Lin

    2 · hunan canc hosp

  • X

    Xiao, Yajie

  • L

    Li, Jia

    2 · hunan canc hosp

  • D

    Du, Haijian

    2

  • Z

    Zhao, Zhikun

  • S

    Sun, Chao

  • Z

    Zhao, Yongtian

  • Y

    Yang, Jie

  • W

    Wu, Dongfang

  • Z

    Zhao, Zhuxiang (通讯)

  • C

    Chen, Bolin (通讯)

    2 · hunan canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417